|
Inhibitory activity against Staphylococcus aureus ATCC 29213 wild type Topo 4
|
Staphylococcus aureus
|
800.0
nM
|
|
|
Inhibitory activity against wild type Escherichia coli gyrase
|
Escherichia coli
|
300.0
nM
|
|
|
Inhibitory activity against wild type Staphylococcus aureus topoisomerase 4
|
Staphylococcus aureus
|
800.0
nM
|
|
|
Inhibition of Staphylococcus aureus topoisomerase 4 by decatenation assay
|
Staphylococcus aureus
|
800.0
nM
|
|
|
Antiproliferative effect against primary human osteoblasts assessed as BrdU incorporation into DNA after 48 hrs
|
Homo sapiens
|
160.0
ug.mL-1
|
|
|
Inhibition of metabolic activity in primary human osteoblasts assessed as MTT reduction after 48 hrs
|
Homo sapiens
|
400.0
ug.mL-1
|
|
|
Antiproliferative effect against MG63 cells assessed as BrdU incorporation into DNA after 48 hrs after 48 hrs
|
Homo sapiens
|
230.0
ug.mL-1
|
|
|
Inhibition of metabolic activity in MG63 cells assessed as MTT reduction after 48 hrs
|
Homo sapiens
|
170.0
ug.mL-1
|
|
|
Antiproliferative effect against HeLa cells after 48 hrs
|
Homo sapiens
|
320.0
ug.mL-1
|
|
|
Inhibition of metabolic activity in HeLa cells assessed as MTT reduction after 48 hrs
|
Homo sapiens
|
110.0
ug.mL-1
|
|
|
Inhibition of Mycobacterium leprae recombinant DNA gyrase expressed in Escherichia coli assessed as inhibition of pBR322 DNA supercoiling
|
Mycobacterium leprae
|
2.0
ug.mL-1
|
|
|
Inhibition of Mycobacterium leprae wild type DNA gyrase A2B2 assessed as DNA supercoiling inhibition
|
Mycobacterium leprae
|
6.0
ug.mL-1
|
|
|
Inhibition of Mycobacterium leprae DNA gyrase subunit A G89C mutant assessed as DNA supercoiling inhibition
|
Mycobacterium leprae
|
30.0
ug.mL-1
|
|
|
Inhibition of Mycobacterium leprae DNA gyrase subunit A A91V mutant assessed as DNA supercoiling inhibition
|
Mycobacterium leprae
|
25.0
ug.mL-1
|
|
|
Inhibition of Mycobacterium leprae wild type DNA gyrase subunit B D205N mutant assessed as DNA supercoiling inhibition
|
Mycobacterium leprae
|
6.0
ug.mL-1
|
|
|
Inhibition of Staphylococcus aureus wild type DNA topoisomerase 4
|
Staphylococcus aureus
|
1.36
ug.mL-1
|
|
|
Inhibition of Staphylococcus aureus DNA topoisomerase 4 Ser80Phe mutant
|
Staphylococcus aureus
|
24.2
ug.mL-1
|
|
|
Inhibition of Staphylococcus aureus wild type DNA gyrase
|
Staphylococcus aureus
|
4.38
ug.mL-1
|
|
|
Inhibition of Staphylococcus aureus DNA gyrase Ser84Leu mutant
|
Staphylococcus aureus
|
512.0
ug.mL-1
|
|
|
Inhibition of Escherichia coli DNA gyrase-mediated supercoiling of pBR322 using bromothymol blue by electrophoresis
|
Escherichia coli
|
0.85
ug.mL-1
|
|
|
Inhibition of Escherichia coli DNA topoisomerase-4-mediated decatenation of pBR322 by electrophoresis
|
Escherichia coli
|
5.0
ug.mL-1
|
|
|
Antimicrobial activity against extracellular Mycobacterium avium subsp. hominissuis ATCC 700898 after 7 days by CLSI method
|
Mycobacterium avium subsp. hominissuis
|
32.0
ug.mL-1
|
|
|
Antimicrobial activity against intracellular Mycobacterium avium subsp. hominissuis ATCC 700898 after 7 days by CLSI method
|
Mycobacterium avium subsp. hominissuis
|
8.24
ug.mL-1
|
|
|
Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 2% FBS
|
Mycobacterium avium subsp. hominissuis
|
8.09
ug.mL-1
|
|
|
Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 10% FBS
|
Mycobacterium avium subsp. hominissuis
|
5.07
ug.mL-1
|
|
|
Antimicrobial activity against Mycobacterium avium subsp. hominissuis ATCC 700898 infected in human THP1 cells in presence of 20% FBS
|
Mycobacterium avium subsp. hominissuis
|
5.21
ug.mL-1
|
|
|
Inhibition of Escherichia coli DNA gyrase assessed as reduction of DNA supercoiling activity using pBR322 DNA substrate after 30 mins by electrophoresis
|
Escherichia coli
|
0.85
ug.mL-1
|
|
|
Inhibition of Escherichia coli topoisomerase 4 assessed as decatenation of kDNA after 30 mins by electrophoresis
|
Escherichia coli
|
5.0
ug.mL-1
|
|
|
Inhibition of human ERG expressed in mammalian cells at 10 uM by patch clamp method
|
Homo sapiens
|
10.0
%
|
|
|
Antimicrobial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by MABA
|
Mycobacterium tuberculosis H37Rv
|
100.0
%
|
|
|
Inhibition of human ERG expressed in CHOK1 cells at 100 uM
|
Homo sapiens
|
42.3
%
|
|
|
Inhibition of human ERG expressed in CHOK1 cells at 30 uM
|
Homo sapiens
|
21.5
%
|
|
|
Inhibition of Mycobacterium leprae DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 2 hrs at 30 degC by ethidium bromide based gel electrophoresis
|
Mycobacterium leprae
|
2.0
ug.mL-1
|
|
|
Inhibition of Mycobacterium tuberculosis DNA gyrase GyrA/GyrB assessed as reduction of enzyme supercoiling activity using relaxed pBR322 DNA substrate incubated for 1 hr at 37 degC by ethidium bromide based gel electrophoresis
|
Mycobacterium tuberculosis
|
2.0
ug.mL-1
|
|
|
Inhibition of Mycobacterium tuberculosis GyrA/GyrB using relaxed pBR322 as substrate at 0.97 uM after 30 mins by DNA supercoiling assay
|
Mycobacterium tuberculosis
|
60.0
%
|
|
|
Cytotoxicity against mouse RAW264.7 cells assessed as inhibition of cell growth at 50 uM after 72 hrs by MTT assay
|
Mus musculus
|
1.26
%
|
|
|
Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 24 hrs by MTT assay
|
Mus musculus
|
379.82
ug.mL-1
|
|
|
Inhibition of human ERG expressed in CHOK1 cells at 30 uM
|
Homo sapiens
|
22.0
%
|
|
|
Inhibition of human ERG expressed in CHOK1 cells at 100 uM
|
Homo sapiens
|
42.0
%
|
|
|
Antimycobacterial activity against Mycobacterium marinum NCTC 2275 by resazurin dye based fluorimetric assay
|
Mycobacterium marinum
|
140.0
nM
|
|
|
Antimycobacterial activity against Mycobacterium avium subsp. avium ATCC 25291 by resazurin dye based fluorimetric assay
|
Mycobacterium avium subsp. avium
|
190.0
nM
|
|
|
Antimycobacterial activity against Mycobacterium bovis BCG ATCC 35737 by resazurin dye based fluorimetric assay
|
Mycobacterium bovis BCG
|
30.0
nM
|
|
|
Inhibition of Mycobacterium tuberculosis DNA gyrase
|
Mycobacterium tuberculosis
|
5.5
ug.mL-1
|
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
29.02
%
|
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.07
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.07
%
|
|
|
Antibacterial activity against Mycobacterium tuberculosis H37Ra ATCC2517 assessed as inhibition of bacterial growth measured after 17 hrs by resazurin based flourimetric assay
|
Mycobacterium tuberculosis
|
250.0
nM
|
|
